Erdafitinib (Johnson & Johnson/Otsuka) is a small molecule inhibitor that targets fibroblast growth factor receptors (FGFRs), which play a role in the angiogenesis pathway, facilitating tumor growth and metastasis. FGFRs are activated by mutation and overexpressed in about 10–20% of patients with urothelial bladder cancer. Early-phase studies of erdafitinib in urothelial bladder cancer have demonstrated promising safety and preliminary efficacy in patients with FGFR pathway alterations.
4 PRODUCT PROFILES
4 erdafitinib : Bladder cancer
7 Figure 1: Erdafitinib for urothelial bladder cancer – SWOT analysis
LIST OF FIGURES
8 Figure 2: Datamonitor Healthcare’s drug assessment summary for erdafitinib in urothelial bladder cancer
9 Figure 3: Datamonitor Healthcare’s drug assessment summary for erdafitinib in urothelial bladder cancer
TABLE OF CONTENTS
5 Table 1: Erdafitinib drug profile
6 Table 2: Key erdafitinib Phase II trial in urothelial bladder cancer
6 Table 3: Erdafitinib early-phase data in urothelial bladder cancer
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726